IC
XENE icon

Ikarian Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Ikarian Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-154,089
Closed -$7.1M – 179
2023
Q4 		$7.1M Buy
154,089
+154,078
+1,400,709% +$5.44M 0.66% 52
2023
Q3 		$37.6K Buy
+11
New +$411 ﹤0.01% 132
2021
Q4 		– Sell
-230,000
Closed -$3.52M – 236
2021
Q3 		$3.52M Buy
+230,000
New +$4M 0.25% 90

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ikarian Capital's XENE Position: Q1 2025 in Review

Ikarian Capital sold out of Xenon Pharmaceuticals (XENE) in Q1 2025, closing a stake of 62,052 shares — an estimated $2.43M sold.

Ikarian Capital first reported a position in XENE in Q4 2019 and held it in 19 quarters. The position peaked at $11.9M in Q2 2021. 206 funds tracked by Wall St. Rank hold XENE as of Q1 2025.

  • Ikarian Capital reported no remaining Xenon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 62,052 Xenon Pharmaceuticals shares in Q1 2025, an estimated $2.43M.
  • Ikarian Capital first reported a position in Xenon Pharmaceuticals in Q4 2019 and held it in 19 quarters.
  • Ikarian Capital's Xenon Pharmaceuticals position peaked at $11.9M in Q2 2021.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.